Based on the above findings, we next investigated whether blocking the regulatory loop by knocking down gankyrin or inhibiting CCR3 serves as an effective strategy for inhibiting the pazopanib resistance of ccRCC in vivo. The gene discussed is CCR3; the disease is nonpapillary renal cell carcinoma.